Medtronic Announces Real-World Data on InPen and Extended Infusion Set* Pivotal Trial Data at the American Diabetes Association 81st Scientific Sessions

 
 

Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced its participation at the American Diabetes Association (ADA) 81 th scientific sessions virtual meeting, June 25-29, 2021 . Medtronic will be participating in this year's ADA virtual sessions with seven data presentations, a product theater, two on-demand learning sessions, and a virtual exhibit. This year Medtronic will showcase its most advanced product portfolio designed to help individuals achieve better glucose control and spend less time managing highs and lows with the right solution, at the right time, no matter where an individual is on their journey with diabetes.

 

  Scientific Presentations
The following poster and oral scientific data presentations represent the work of Medtronic employees and/or independent investigators using Medtronic devices in their research. Poster presentations will be available to all attendees for viewing with an option to query presenters throughout the conference.

 

   InPen™ Smart Insulin Pen   

 
  • "Impact of InPen™ smart insulin pen use on real-world glycemic and insulin dosing outcomes in individuals with poorly controlled diabetes" – oral presentation by Robert Vigersky, M.D. on Sunday, June 27 at 6:15 p.m. ET .
  •  
  • "Glycemic outcomes of new InPen™ smart insulin pen users who received virtual onboarding" – poster presentation by Madison Smith , Ph.D., R.N.
  •  

   Medtronic Extended Infusion Set*   

 
  • "Infusion Set Survival and Performance During the Medtronic Extended-Wear Infusion Set (EWIS) Pivotal Trial" – poster presentation by Bruce Buckingham , M.D.
  •  
  • "Patient Reported Satisfaction During the Medtronic Extended-Wear Infusion Set (EWIS) Pivotal Trial" – poster presentation by Ron Brazg , M.D., FACE.
  •  

   Hybrid Closed-Loop (HCL)   

 
  • "Closed-Loop Increases Time-in-Range in Older Adults with Type 1 Diabetes Compared with Sensor- Augmented Pump Therapy: A Randomized Crossover Trial" – independent oral presentation by Sybil McAuley , MBBS, Ph.D., FRACP, on Sunday, June 27 at 4:30 p.m. ET .
  •  
  • "Durable insulin pumps vs. multiple daily injections for type 1 diabetes: Healthcare utilization and A1C" – poster presentation by Mona Shah , M.S.
  •  

   Advanced Hybrid Closed-Loop (AHCL)*   

 
  • "Robust glycemic outcomes after MiniMed™ Advanced Hybrid Closed-Loop (AHCL) System use regardless of previous therapy" – poster presentation by John Shin , Ph.D., MBA.
  •  

  Conference Events
Medtronic will host a product theater and offer two on-demand Learning Bytes that will focus on the outcomes to date with InPen™ and the MiniMed™ 770G and MiniMed™ 780G systems. The product theatre will also feature a patient panel and a look at the Medtronic technology roadmap.

 
  • "Shared Decision with Diabetes Technology" - product theater live on Friday, June 25 at 10:00 a.m. ET then available on-demand. Speakers and topics to be presented will include:
  •  
 
            
 

   Janice MacLeod,   

 

  M.A., R.D., CDCES, FADCES,  

 

  head of clinical advocacy,  

 

  Medtronic Diabetes  

 
 

  Introduction and Insulin 100  

 
 

   Diana Isaacs,   

 

  PharmD, BCPS, BC-ADM, CDCES, FADCES  

 

  Cleveland Clinic  

 
 

  Smart MDI Therapy: Smart Insulin Pens and CGM are Improving MDI Therapy  

 
 

   Robert Vigersky,   

 

  M.D. and chief medical officer,  

 

  global medical & clinical affairs,   Medtronic Diabetes  

 
 

  MiniMed™ 770G and 780G Systems: Proven Outcomes in Clinical Trials and Real-World Data in Pediatric and Adult Populations  

 
 

   Diana Isaacs,   

 

  PharmD, BCPS, BC-ADM, CDCES, FADCES  

 
 

  Patient Ambassador Panel  

 
 

   Ali Dianaty,   

 

  vice president, product innovation,  

 

  Medtronic Diabetes  

 
 

  Looking Toward the Future: Next Steps in the Advancement of Closing the Loop  

 
 

   Janice MacLeod,   

 

  M.A., R.D., CDCES, FADCES,  

 

  head of clinical advocacy,  

 

  Medtronic Diabetes  

 
 

  Q & A  

 
 
 
  • "Tips for Success When Transitioning Patient from Multiple Daily Injection (MDI) to Insulin Pump Therapy" – on-demand Learning Byte presented by Laurie Jung , R.D., CDCES, opening on Thursday, June 24 at 8:00 a.m. ET .
  •  
  • "InPen™ Smart Insulin Pen: Product Features and Overview" – on-demand Learning Byte presented by Diana Isaacs , PharmD, BCPS, BC-ADM, CDCES, FADCES, opening on Thursday, June 24 at 8:00 a.m. ET .
  •  

In addition, the Medtronic 24-hour virtual exhibit booth will feature the company's full portfolio of diabetes technologies, spanning smart MDI therapy with the InPen smart insulin pen system and advanced insulin pump technology like the MiniMed 770G insulin pump system. The exhibit will also highlight personalized service and support offerings, including those that enable remote and virtual care.

 

   About the Diabetes Business at Medtronic   ( www.medtronicdiabetes.com )
Medtronic is working together with the global community to change the way people manage diabetes. The company aims to transform diabetes care by expanding access, integrating care, and improving outcomes, so people living with diabetes can enjoy greater freedom and better health.

 

   About Medtronic
 
Medtronic plc ( www.medtronic.com ), headquartered in Dublin, Ireland , is among the world's largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals, and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

 

*CAUTION – Investigational device. Limited by U.S. law to investigational use. Not approved or cleared by United States Food and Drug Administration (FDA) and not for sale in the U.S.

 

  Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.  

 

  Contacts:  

 

  Kendra Cassillo  
Public Relations
+1-818-576-5611

 

 

 

  Ryan Weispfenning  
Investor Relations
+1-763-505-4626

 
 

  Medtronic plc (PRNewsfoto/Medtronic plc) 

 
 

 

 
 
 

 Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/medtronic-announces-real-world-data-on-inpen-and-extended-infusion-set-pivotal-trial-data-at-the-american-diabetes-association-81st-scientific-sessions-301317852.html  

 

SOURCE Medtronic plc

 

 

 

 Cision View original content to download multimedia: https://www.newswire.ca/en/releases/archive/June2021/23/c2833.html  

 
 

News Provided by Canada Newswire via QuoteMedia

The Conversation (0)
illustration of brain and cell phone.

BlinkLab Completes First Patient Test for US Autism Diagnostic Study

Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared at validating the company's Dx1 test as a diagnostic aid for clinicians.

BlinkLab states in its Wednesday (March 12) release that the study is the largest digital diagnostic trial for autism in the US, with its aim being to support the early detection of developmental conditions like autism.

The first patient test took place at PriMED Clinical Research in Dayton, Ohio. PriMED, a division of PriMED Physicians, is one of two clinical sites selected for the study’s initial phase, which is targeting 100 patients.

Keep reading...Show less
HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Limited (ASX: HMD), a medical data and technology company leading the digital transformation of maternity care, is delighted to announce it has entered into a collaboration agreement with Garmin (NYSE: GRMN), a leading global provider of smartwatches and GPS-enabled products, aimed at enhancing remote pregnancy monitoring and expanding the range of health data available to expectant mothers and their healthcare providers.

Keep reading...Show less
Cardiologist wearing virtual reality glasses.

2 Biggest Medical Device ETFs in 2025

Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.

Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or a mix of both. Aside from stocks, some ETFs also track commodities or bonds.

In the healthcare industry, medical device ETFs bring together companies that go to great lengths to develop pharmaceutical-based technology that can improve the lives of patients.

Keep reading...Show less
Cyclomedica

Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

Cyclopharm Limited (ASX: CYC) is pleased to announce the signing of a major contract with Hospital Corporation of America Healthcare (HCA), one of the largest single healthcare providers in the United States. This agreement marks a significant milestone for the company which will allow the deployment of Technegas® in up to 169 nuclear medicine departments across HCA’s extensive network.1

Keep reading...Show less
CONNEQT App Launches in USA as Pulse Deliveries Commence

CONNEQT App Launches in USA as Pulse Deliveries Commence

Cardiex Limited (CDX:AU) has announced CONNEQT App Launches in USA as Pulse Deliveries Commence

Download the PDF here.

Female doctor with clipboard talking to smiling female patient at hospital.

Revolutionizing Women's Health: Antifungal Innovation Brings New Investment Opportunities

The intersection of women's health and antifungal innovation represents a pivotal moment in healthcare, offering both transformative medical advancements and compelling investment opportunities.

The groundbreaking developments in antifungal treatments specifically targeting women's health issues present a substantial market potential, resulting in rising investor interest in this rapidly evolving sector.

Despite comprising half the global population, women face unique health challenges that have historically received insufficient attention and investment. Among these health challenges, vaginal candidiasis stands out as a persistent and widespread issue affecting millions of women worldwide.

Keep reading...Show less

Latest Press Releases

Related News

×